Variable | Prematching | Postmatching^{a} | ||||
---|---|---|---|---|---|---|

No PLEX n=200 (79.7%) | PLEX n=51 (20.3%) | P value^{b} | No PLEX n=45 (22.5%) | PLEX n=45 (88.2%) | P value^{b} | |

Outcomes | ||||||

Vasculitis activity, n (%) | ||||||

Remission | ||||||

6 mo | 132 (78.1) | 36 (73.5) | 0.497 | |||

Total^{c} | 155 (88.6) | 43 (87.8) | 0.875 | |||

Complete remission | ||||||

6 mo | 35 (21.7) | 11 (23.9) | 0.754 | |||

Total^{c} | 91 (52.0) | 28 (57.1) | 0.516 | |||

Renal remission | ||||||

6 mo | 139 (79.4) | 38 (77.6) | 0.775 | |||

Total^{c} | 155 (88.6) | 44 (89.8) | 0.810 | |||

Relapse | ||||||

12 mo | 25 (13.1) | 7 (14.9) | 0.745 | |||

Total^{c} | 62 (37.8) | 19 (38.8) | 0.902 | |||

Renal relapse | 36 (59.0) | 10 (52.6) | 0.623 | |||

Death | ||||||

24 mo | 18 (9.0) | 4 (7.8) | 0.794 | |||

Total^{c} | 45 (22.5) | 17 (33.3) | 0.109 | |||

Renal recovery, n (%) | ||||||

ESKD | ||||||

24 mo | 42 (21.0) | 17 (33.3) | 0.064 | |||

Total^{c} | 57 (28.5) | 21 (41.2) | 0.081 | |||

Dialysis (total) | 34 (17.0) | 20 (39.3) | <0.0001 | 7 (15.5) | 16 (35.5) | 0.087 |

Renal function recovery after 6 mo to an eGFR>30 ml/min per 1.73 m^{2} | 61 (50.0) | 17 (44.7) | 0.571 | |||

Combined events of ESKD and/or death, n (%) | ||||||

18 mo | 49 (24.5) | 18 (35.3) | 0.120 | 15 (33.3) | 15 (33.3) | 0.99 |

24 mo | 51 (25.5) | 18 (35.3) | 0.162 | 16 (35.6) | 15 (33.3) | 0.824 |

Total^{c} | 85 (42.5) | 29 (56.9) | 0.066 | 24 (53.3) | 25 (55.6) | 0.832 |

Time to event, median (IQR) mo | ||||||

Remission | 3.7 (2.6–5.4) | 3.5 (2.4–6.0) | 0.926 | |||

Relapse | 16.3 (9.7–37.1) | 23.8 (9.6–108.5) | 0.372 | |||

Death | 39 (11.3–112.5) | 51 (6.0–71.5) | 0.658 | |||

ESKD | 3.4 (0.2–33.1) | 1.8 (0.0–14.7) | 0.795 | |||

Combined events | 10.9 (0.7–58.6) | 21.8 (0.1–50.8) | 0.667 | 5.4 (0.26–38.5) | 6.6 (0.45–55.0) | 0.756 |

Time of FU after renal involvement, median (IQR) yr | 4.6 (1.2–10.5) | 5.0 (3.2–7.6) | 0.707 | |||

Time of FU, median (IQR) yr | 5.5 (1.4–11.4) | 6.6 (3.5–12.1) | 0.352 |

Population follow-up: 6 mo, no PLEX:

*n*=172 versus PLEX:*n*=45; 12 mo, no PLEX:*n*=157 versus PLEX:*n*=45; 18 mo, no PLEX:*n*=147 versus PLEX:*n*=43; 24 mo, no PLEX:*n*=142 versus PLEX:*n*=39. IQR, interquartile range; FU, follow-up.↵a The pairs resultant from the PS matching were obtained by the analysis of the outcome of combined events of ESKD and/or death at 18 mo. Therefore, the comparisons pertaining to other outcomes are not shown.

↵b

*P*value <0.05 is considered significant (Pearson chi-squared test for categoric variables,*t*test for continuous variables with normal distribution, and Mann–Whitney*U*test for continuous variables with skewed distribution).↵c “Total” refers to the number of occurrences during all follow-up time.